REGENXBIO Inc. (RGNX) Quick Ratio
- Quick ratio · latest quarter: Value 2.57×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.57× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $212.27M ÷ $82.62M ≈ 2.57× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 212.27M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 82.62M USD | Liabilities, Current |
| Cash and equivalents | 36.49M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 69.03M USD | Marketable Securities, Current |
| Customer receivables | 106.75M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $212.27M | $82.62M | $36.49M | $69.03M | $106.75M | (m) | 2.57× |
| 2026-03-31 | $160.53M | $71.11M | $15.23M | $135.26M | $10.04M | (m) | 2.26× |
| 2025-12-31 | $256.45M | $118.09M | $34.47M | $195.60M | $26.38M | (m) | 2.17× |
| 2025-09-30 | $299.55M | $124.57M | $58.80M | $215.40M | $25.35M | (m) | 2.40× |
| 2025-06-30 | $343.50M | $119.54M | $79.56M | $243.74M | $20.20M | (m) | 2.87× |
| 2025-03-31 | $286.06M | $106.73M | $130.10M | $137.76M | $18.19M | (m) | 2.68× |
| 2024-12-31 | $255.16M | $103.19M | $57.53M | $177.16M | $20.47M | (m) | 2.47× |
| 2024-09-30 | $279.06M | $102.72M | $56.62M | $198.84M | $23.60M | (m) | 2.72× |
| 2024-06-30 | $313.17M | $98.27M | $57.77M | $232.59M | $22.81M | (m) | 3.19× |
| 2024-03-31 | $354.53M | $110.18M | $112.97M | $225.73M | $15.83M | (m) | 3.22× |
| 2023-12-31 | $300.05M | $130.27M | $34.52M | $240.74M | $24.79M | (m) | 2.30× |
| 2023-09-30 | $329.93M | $127.35M | $53.05M | $248.84M | $28.04M | (m) | 2.59× |
| 2023-06-30 | $341.46M | $117.89M | $68.60M | $251.48M | $21.38M | (m) | 2.90× |
| 2023-03-31 | $350.68M | $112.33M | $70.09M | $261.73M | $18.86M | (m) | 3.12× |
| 2022-12-31 | $392.72M | $130.43M | $96.95M | $267.69M | $28.08M | (m) | 3.01× |
| 2022-09-30 | $414.97M | $123.55M | $118.54M | $263.87M | $32.55M | (m) | 3.36× |
| 2022-06-30 | $440.46M | $114.56M | $121.37M | $281.59M | $37.50M | (m) | 3.84× |
| 2022-03-31 | $421.16M | $119.94M | $191.87M | $202.26M | $27.02M | (m) | 3.51× |
| 2021-12-31 | $489.88M | $130.47M | $345.21M | $112.23M | $32.44M | (m) | 3.75× |
| 2021-09-30 | $385.88M | $106.77M | $228.39M | $111.47M | $46.02M | (m) | 3.61× |
| 2021-06-30 | $419.13M | $91.55M | $257.07M | $117.67M | $44.39M | (m) | 4.58× |
| 2021-03-31 | $481.92M | $83.96M | $291.48M | $149.40M | $41.04M | (m) | 5.74× |
| 2020-12-31 | $518.74M | $81.45M | $338.43M | $137.31M | $43.00M | (m) | 6.37× |
| 2020-09-30 | $363.64M | $63.61M | $93.22M | $148.31M | $122.12M | (m) | 5.72× |
| 2020-06-30 | (m) | $40.20M | $94.22M | $174.96M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $31.79M | $69.41M | $209.85M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $33.68M | $69.51M | $226.70M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $31.34M | $79.59M | $252.13M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $24.66M | $55.14M | $286.35M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $21.39M | $55.85M | $229.37M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $22.18M | $75.56M | $244.20M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $19.12M | $142.42M | $230.17M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $16.85M | $106.89M | $179.60M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $14.88M | $71.87M | $158.00M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $14.44M | $46.66M | $114.12M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $13.40M | $59.88M | $106.78M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $11.46M | $57.65M | $104.43M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $9.96M | $82.05M | $63.76M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $9.67M | $24.84M | $64.71M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $14.38M | $28.11M | $63.66M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $9.15M | $30.08M | $64.12M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $5.78M | $35.51M | $65.54M | (m) | (m) | (m) |
| 2015-12-31 | $116.28M | $4.34M | $54.12M | $60.02M | $2.14M | (m) | 26.80× |
| 2015-09-30 | (m) | $5.31M | $205.32M | $8.03M | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $85.22M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $25.37M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $9.19M | $1.12M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $982.00K | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $1.12M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $2.17M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |